3. Publikationsliste. Prim. Univ.-Prof. Dr. Andreas Petzer. Abteilung Interne I: Internistische Hämatologie, Onkologie und Gastroenterologie

Transcription

1 3. Publikationsliste Prim. Univ.-Prof. Dr. Andreas Petzer Abteilung Interne I: Internistische Hämatologie, Onkologie und Gastroenterologie 1

2 I. Originalarbeiten Vor der Habilitation: 1. Schulz T. F., Helmberg A., Hosp M., Petzer A., Föger B. and Dierich M.P. (1985) Enzyme-linked immunoassay to monitor the purification of, and screen for monoclonal antibodies against, C3b receptor. Complement, 2, Dierich M. P., Erdei A., Huemer H., Petzer A., Stauder R., Schulz T. F. and Gergely J. (1987) Involvement of complement in B-cell, T-cell and monocyte/macrophage activation. Immunology Letters, 14: Petzer A. L., Schulz T. F., Stauder R., Eigentler A., Myones B. L. and Dierich M.P.(1988) Structural and functional analysis of CR2/EBV receptor by means of monoclonal antibodies and limited tryptic digestion. Immunology, 63: Pernegger G., Schulz T. F., Hosp M., Myones B. L., Petzer A. L., Eigentler A., Böck G., Wick G. and Dierich M. P.(1988) Cell cycle control of a Burkitt lymphoma cell line: responsiveness to growth signals engaging the C3D/EBV receptor. Immunology, 65: Eigentler A., Schulz T.F., Larcher C., Breitwieser E., Myones B.L., Petzer A.L.and Dierich M.P. (1989) C3bi-binding protein on Candida albicans: Its temperature-dependent expression and its relationship to human complement receptor typ 3. Infection & Immunity, 57/2:

3 6. Petzer A. L., Bilgeri R., Zilian U., Haun M., Geisen F.H., Pragnell I., Braunsteiner H. and Konwalinka G. (1991) The Inhibitory Effect of 2-Chlorodeoxyadenosine on Granulocytic, Erythroid and T-lymphocytic Colony Growth. Blood, Vol 78: No Bilgeri R., Petzer A.L., Zilian U., Geisen F.H., Schirmer M., Haun M., Braunsteiner H, Konwalinka G. (1993) Effect of deoxycytidine on 2-chlorodeoxyadenosine-mediated growth inhibition of normal human erythroid and myeloid progenitor cells.exp. Hematol., 21: Holyoake T.L., Freshney M.G., Konwalinka G., Haun M., Petzer A., Fitzsimons E., Lucie N.P., Wright E.G., Pragnell I.B. (1993) Mixed colony formation in vitro by the heterogenous compartment of multipotential progenitors in human bone marrow. Leukemia, Vol 7, No 2: Huemer H.P., Larcher C., Prodinger W.M., Petzer A.L., Mitterer M., Falser N. (1993) Determination of soluble CD21 as a parameter of B cell activation. Clin. Exp. Immunol., 93: Petzer A.L., Geisen F., Bilgeri R., Zilian U., Haun M., Herold M., Konwalinka G., Braunsteiner H. (1995) Growth-inhibitory effect of 2-chlorodeoxyadenosine (2-CdA) on myeloid CFU-GM progenitors in normal human long-term bone marrow cultures and its compensation by G-CSF or IL-3. Exp. Hematol., 23:

4 11. Konwalinka G., Schirmer M., Hilbe W., Fend F., Geisen F., Knoblechner A., Petzer A., Thaler J. (1995) Minimal residual disease in hairy-cell leukemia after treatment with 2-Chlorodeoxyadenosine. Blood Cells, 21(14) July 31: Petzer A.L., Hogge D.E., Lansdorp P.M., Reid D.S., Eaves C.J. (1996) Self-renewal of primitive human hematopoietic cells (LTC- IC) in vitro and their expansion in defined media. Proc. Natl. Acad. Sci. USA, Vol.93, Feb. 1996: Petzer A.L., Zandstra P.W., Piret J.M, Eaves C.J. (1996) Differential cytokine effects on primitive (CD34 + CD38 - ) human hematopoietic cells: Novel responses to Flt3-Ligand and thrombopoietin. J. Exp. Med., Vol.183, June 1996: Petzer AL, Eaves CJ, Lansdorp PM, Ponchio L, Barnett M, Eaves AC. (1996) Characterization of primitive subpopulations of normal and leukemic cells present in the blood of patients with newly diagnosed as well as established chronic myeloid leukemia. Blood, Vol.88, Sept. 1996: Maguer-Satta V, Petzer AL, Eaves AC, Eaves CJ (1996) BCR- ABL expression in different subpopulations of functionally characterized Ph + CD34 + cells from patients with chronic myeloid leukemia. Blood, Vol.88, Sept 1996:

5 Nach der Habilitation: 16. Zandstra P.W., Petzer A.L., Eaves C.J., Piret J.M, (1997) Cellular determinants affecting the rate of cytokine depletion in cultures of human hematopoietic cells. Biotechnology & Bioengineering, Vol.54, No.1, April 5, Hogge D, Fanning S, Bockhold K, Petzer A.L., Lambie K, Lansdorp P, Eaves AC, Eaves C.J. (1997) Quantitation and characterization of human megakaryocyte colony-forming cells using a standardized serum-free agarose assay. Br. J. Haematology, Vol. 96: Zandstra P.W., Conneally E, Petzer A.L., Piret J.M, Eaves C.J.(1997) Cytokine manipulation of primitive human hematopoietic cell self-renewal. Proc. Natl. Acad. Sci. USA, Vol. 94, April 1997: Petzer AL, Eaves CJ, Barnett M, Eaves AC. (1997) Selective expansion of primitive normal hematopoietic cells in cytokinesupplemented cultures of purified cells from patients with chronic myeloid leukemia. Blood, Vol 90, July 1997: Gunsilius E, Petzer A, Gastl G.(1997) Hochdosistherapie mit Transplantation autologer peripherer hämatopoetischer Stammzellen (High dose therapy with autologous peripheral stem cell transplantation) I. Grundlagen und klinische Entwicklung (I. Basic principles and clinical development). Acta Medica Austriaca, Vol 24(3):

6 21. Gunsilius E, Petzer A, Gastl G.(1997) Hochdosistherapie mit Transplantation autologer peripherer hämatopoetischer Stammzellen (High dose therapy with autologous peripheral stem cell transplantation) II. Indikationen und klinische Ergebnisse (II. Indications and clinivcal results). Acta Medica Austriaca, Vol 24(3): Conneally E, Cashman J, Petzer A, Eaves C (1997) Expansion in vitro of transplantable human cord blood stem cells demonstrated using a quantitative assay of their lympho-myeloid repopulating activity in nonobese diabetic-scid mice. PNAS 1997, Sept. 2, Vol.94(18): Eaves C, Miller C, Cashman J, Conneally E, Petzer A, Zandstra P, Eaves A. (1997). Hematopoietic Stem Cells: Inferences from In Vivo Assays. Stem Cells 1997, Vol.15 (suppl 1): Eaves C, Zandstra P, Conneally E, Miller C, Cashman J, Petzer A, Piret J. (1998). Changes in the cytokine regulation of stem cell self- renewal during ontogeny. Stem Cells 1998, 16 (suppl 1): Eaves AC, Barnett MJ, Ponchio L, Cashman JD, Petzer AL, Eaves CJ. (1998). Differences between normal and CML stem cells Potential targets for clinical exploitation. Stem Cells 1998, 16 (suppl 1):

7 26. Petzer AL, Conneally E, Zandstra PW, Cashman JD, Gastl G, Eaves AC, Eaves CJ. (1998). In vitro expansion of primitive progenitors (LTC-IC, CRU) under defined culture conditions. Bone Marrow Transplantation, 22, Suppl.3: S Gunsilius E, Lass-Flörl C, Mur E, Gabl C, Gastl G, Petzer AL. (1999) Aspergillus arthritis in acute lymphoblastic leukemia. Ann. Hematol., 78: Gunsilius E, Petzer A, Stockhammer G, Nussbaumer W, Schumacher P, Clausen J, Gastl G. (2000). Thrombocytes are the major source for soluble vascular endothelial growth factor in the peripheral blood. Oncology, 58: Petzer AL, Gunsilius E, Zech N, Clausen J, Hoflehner E, Nussbaumer W, Gastl G. (2000). Evaluation of optimal survival of primitive progenitor cells (LTC-IC) from PBPC apheresis products after overnight storage. Bone Marrow Transplantation, 25: Gunsilius E*, Duba H-Ch*, Petzer AL*, Kähler CM*, Grünewald K, Stockhammer G, Gabl Ch, Dirnhofer S, Clausen J, Gastl G. (2000) Evidence from a leukaemia model for the maintenance of the blood vascular endothelium by bone-marrow derived endothelial cells. Lancet, 355: , mit Editorial; *equal contribution 31. Gunsilius E, Lass-Flörl C, Kähler C, Gastl G and Petzer A (2001). Candida ciferrii, another fluconazole-resistant yeast causing systemic mycosis in immunocompromised patients. Ann. Hematol; 80(3):

8 32. Clausen J, Petzer AL, Vergeiner B, Enk M, Gastl G and Gunsilius E. (2001). Optimal Timing for the Collection and In Vitro Expansion of Cytotoxic CD56 + Lymphocytes from Patients Undergoing Autologous Peripheral Blood Stem Cell Transplantation. Journal of Hematotherapy and Stem Cell Research; 10 (4): Gunsilius E, Gastl G, Petzer AL (2001). Hematopoietic stem cells. Biomed Pharmacother; 55 (4) : Lass-Flörl C, Aigner J, Gunsilius E, Petzer A, Nachbaur D, Gastl G, Einsele H, Löffler J, Dierich MP, Würzner R (2001). Screening for Aspergillus spp. using polymerase chain reaction of whole blood samples from patients with haematological malignancies. British Journal of Haematology; 113 (1), Petzer AL, Hochenburger E, Haun M, Duba HC, Grünewald K, Hoflehner E, Sill H, Linkesch W, Gastl G, Gunsilius E (2002). High-dose hydroxyurea plus G-CSF mobilize BCR-ABL- negative progenitor cells (CFC, LTC-IC) into the blood of newly diagnosed CML patients at any time of hematopoietic regeneration. J Hematother Stem Cell Res; 11(2): Petzer AL, Speth HG, Hoflehner E, Clausen J, Nachbaur D, Gastl G, Gunsilius E (2002). Breaking the rules? X-ray examination of haematopoietic stem cell grafts at international airports. Blood; 99 (12): Petzer AL, Gunsilius E, Hayes M, Stockhammer G, Duba HC, Schneller F, Grünewald K, Poewe W, Gastl G (2002). Low concentraions of STI571 in the cerebrospinal fluid: a case report. Br J Hematol; 117(3):

9 38. Keil F, Elahi F, Greinix HT, Fritsch G, Louda N, Petzer AL, Prinz E, Wagner T, Kalhs P, Lechner K, Geissler K (2002). Ex vivo expansion of long-term culture initiaing marrow cells by IL-10, SCF, and IL-3. Transfusion; 42(5): Gunsilius E, Tschmelitsch J, Eberwein M, Schwelberger H, Spizzo G, Kahler CM, Stockhammer G, Lang A, Petzer AL, Gastl G. (2002). In vivo release of vascular endothelial growth factor from colorectal carcinomas. Oncology; 62(4): Clausen J, Vergeiner B, Enk M, Petzer AL, Gastl G, Gunsilius E (2003). Functional significance of the activation-associated receptors CD25 and CD69 on human NK-cells and NK-like T-cells. Immunobiol.; 207: Lass-Flörl C, Gunsilius E, Gastl G, Englisch M, Koch G, Ulmer H, Dierich MP, Petzer A (2003). Fungal colonization in neutropenic patients: a randomized, double-blind study comparing itraconazole solution and amphotericin B solution. Annals of Hematology; 82: Zech NH, Gunsilius E, Clausen J, Hoflehner E, Hoelzler K, Gastl G, Petzer AL (2003). Expansion of Mobilized Peripheral Blood Progenitor Cells under Defined Culture Conditions using CD34+CD71-CD45- Cells as Starting Population. J of Hematotherapy and Stem Cell Research; 12: Petzer A, Gunsilius G (2003). Hematopoietic Stem Cells in Chronic Myeloid Leukemia. Archives of Medical Research, Vol 34, Issue 6: (Review Article) 9

10 44. Lass-Flörl C, Gunsilius E, Gastl G, Bonatti H, Freund MC, Gschwendtner A, Kropshofer G, Dierich MP and Petzer A. (2004). Diagnosing invasive asperigillosis during antifungal therapy by PCR analysis of blood samples. Journal of Clinical Microbiology; 42 (9): Clausen J, Enk M, Vergeiner B,EisendleK, Glassl H, Petzer AL,Gastl G, Gunsilius E. (2004) Suppression of Natural Killer Cells in the presence of CD34+ blood progenitor cells and peripheral blood lymphocytes. Biol Blood Marrow Transplant 10(10): Eisterer W, Jiang X,Christ O, Glimm H, Lee KH, Pang E, Lambie K, Shaw G, Holyoake TL, Petzer AL, Auewarakul Ch, Barnett MJ, Eaves CJ, Eaves AC (2004). Different subsets of primary Chronic Myeloid Leukemia Stem Cells engraft immnodeficient mice and produce a model of the human disease. Leukemia 47. Cornelia Lass-Flörl, Karharina Griff, Astrid Mayr, Andreas Petzer, Günter Gastl, Hugo Bonatti, Martin Freund, Gabriele Kropshofer, Manfred P. Dierich and David Nachbaur (2005). Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience. British Journal of Haematology; 131: RF Schlenk, U Germing, F Hartmann, A Glasmacher, JT Fischer, F del Valle y Fuentes, K Götze, H Pralle, C Nerl, H Salwender, W Grimminger, A Petzer, M Hensel, A Benner, L Zick, K Döhner, S Fröhling and H Döhner, for the AML Studiy Group (AMLSG) (2005). High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia. Leukemia; 9: J. Clausen, D. Wolf, A.L. Petzer, E. Gunsilius, P. Schumacher, B. Kircher, G. Gastl and D. Nachbaur (2007). Impact of natural killer cell dose and donor 10

11 killer-cell immunoglobulin-like receptor (KIR) genotype on outcome following human leucocyte antigen-identical haematopoietic stem cell transplantation. Britisch Society for Immunology, Clinical and Experimental Immunology; 148/3: Günther F. Körmöczi, Eva-Maria Dauber, Oskar A. Haas, Gerhard Fritsch, Markus Raderer, Christoph Buchta, Andreas L. Petzer, Diether Schönitzer, Wolfgang R. Mayr, Christoph Gassner (2007). Mosaicism due to myeloid lineage-restricted loss of heterozygosity as cause of spontaneous Rh phenotype splitting. Blood; 110/6: Jutta Auberger, Johannes Clausen, Martin Erdel, Eberhard Gunsilius, Andreas Petzer, Günther Gastl and David Nachbaur (2007). Fludarabine/intermediatedose cytarabine with or without allogeneic hematopoietic stem cell transplantation in poor-risk leukemia: a single center experience. Int J Hematol; 87(4): Kircher Brigitte, Schumacher Petra, Petzer Andreas, Hoflehner Elisabeth, Nachbaur David, Gastl Günther (2007). Anti-leukemic activity of valproic acid and imatinib mesylate on human Ph+ ALL and CML cells in vitro. Eur J Haematol; Epub ahead of print. 53. Ernst Rechberger, Gerald Webersinke, Andreas Petzer (2008). Chronische Myeloproliferative Erkrankungen (CMPE). Wiener Klinische Wochenschrift; 01: Peter Valent, Thomas Lion, Dominik Wolf, Christian Sillaber, Hermine Agis, Andreas Petzer, Alois Lang, Peter Kahls, Dietmar Geissler, Richard Greil, Werner Linkesch, Sonja Burgstaller, Josef Thaler, Günther Gastl (2008) Diagnostic algorithms, monitoring, prognostication, and therapy in chronic myeloid leukemia (CML): a proposal of the Austrian CML platform. Wiener Klinische Wochenschrift; Vol. 120, 21:

12 55. Josef Hammer, Christine Track, Dietmar H. Seewald, Kurt J. Spiegl, Johannes Feichtinger, Andreas L. Petzer, Werner Langsteger, Sabine Pöstlberger, Elsisabeth Bräutigam (2009) Local Relapse fter Breast-Conserving Surgery and Radiotherapy Effects on Survival Parameters. Strahlentherapie und Onkologie; 7: Andreas L. Petzer, Dominik Wolf, Dominic Fong, Thomas Lion Irina Dyagil, Zvenyslava Masliak, Andrija Bogdanovic, Laimonas Griskevicius, Sandra Lejniece, Stefan Goranov, Liana Gercheva, Aleksandar Stojanovic, Dontcho Peytchev, Nikolay Tzvetkov, Rasa Griniute, Radka Oucheva, Hanno Ulmer, Marthin Kwakkelstein, Francesca Rancati, Guenther Gastl (2010). High dose imatinib improves cytogenetic and molecular remissions in pretreated Ph+/BCR-ABL+ CML chronic phase patients: First results from a randomized CELSG CML 11 Phase III ISTAHIT Study. Haematologica; 95(6): R. Schlenk, K. Döhner, S. Mack, M. Stoppel, F. Király, K. Götze, F. Hartmann, H.A. Heinz, E. Koller, A.L. Petzer, W. Grimminger, G. Kobbe, A. Glasmacher, H. Salwender, H. Kirchen, D. Haase, S. Kremers, A Matzdorff, A. Benner, H. Döhner (2010) Prospective evaluation of allogeneic hematopoietic stem cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A. JCO; 28: K. Kurz, K. Garimorth, M. Joannidis, D. Fuchs, A.L. Petzer, G. Weiss (2010) Altered immune responses during septicaemia in patients suffering from haematological malignancies eingereicht! II. Letters to the Editor, Editorials, Kommentare Vor der Hamilitation: 1. Hengster P., Kofler H., Eigentler A., Larcher C., Petzer A., Schulz T., Fritsch P. and Dierich M.P. (1986) Efficacy of Pasteur Hepatitis B vaccine in medical students. Letter to Lancet, Dec.6,

13 2. Wiedermann C.J., Bilgeri R., Petzer A., Gattringer C., Geissler D., Konwalinka G. (1989) Multipotent stem cell origin of myelodysplastic syndromes. Letter to Blood, Vol 73, Nach der Habilitation: 3. Gunsilius E, Petzer AL, Gastl G. (1999) Space flight and growth factors. Letter to Lancet, May 1, 353 (9163): Gunsilius E, Petzer AL, Gastl G. (1999) Vascular endothelial growth factor platelet counts and renal cancer. Letter to Lancet, June 26, 353 (9171): Gunsilius E, Petzer AL, Gastl G. (1999) Correspondence re: P. Salven et al., leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor. Clin. Cancer Res., 5: Gunsilius E, Petzer AL, Gastl G. (2000) Angiogenic growth factors and endostatin in non-hodgkin's lymphoma. Br J Haematol; 108 (3): Gunsilius E, Duba HC, Petzer AL, Kahler CM, Gastl GA (2000). Reply (Angiogenesis in chronic meylogenous leukemia). Lancet; 356 (Issue 9284): Gunsilius E, Tschmelitsch J, Petzer AL (2001). Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer; clinical evidence of platelet scavenging? Clin Cancer Res.; 7 (2): Gunsilius E, Petzer AL, Stockhammer G, Kähler CM, Gastl G (2001). Serial Measurement of Vascular Endothelial Growth Factor and Transforming Growth Factor-ss1 in Serumof Patients with Acute Ischemic Stroke. Stroke; 32(1):

14 10. Gunsilius E, Duba HC, Petzer AL, Kähler CM, Gastl GA (2001). Contribution of Endothelial Cells of Hematopoietic Origin to Blood Vessel Formation. Circ Res; 88(1). 11. Gunsilius E, Petzer AL, Duba HC, Kähler CM, Gastl G (2001). Circulating endothelial cells after transplantation. Lancet; 357 (9266): Gunsilius E, Petzer AL, Gastl GA (2002). Blood levels of vascular endothelial growth factor in obstructive sleep apnea-hypopnea syndrome. Blood; 99(1):

15 III. Bücher, Buchbeiträge, etc. Vor der Habilitation: 1. Stauder R, Schulz T.F., Petzer A., Eigentler A. and Dierich M.P. (1987) Identification of antibodies to leucocyte membrane-associated C3-binding proteins. Leukocyte Typing III - White Cell Differentiation Antigens (McMichael, A.J., Ed.) Oxford University Press, Konwalinka G., Wiedermann C.J., Petzer A., Grünewald K., Breier C., Geissler D. (1988) Stimulation of early and late erythropoietic progenitor cells by insulin: evidence for different mechanisms. Molecular Biology of Hematopoiesis, ed. by Mehdi Tavassoli, Esmail D. Zanjani, Joaon L. Ascensao, Nader G. Abraham and Alan S. Levine (Plenum Publishing Corporation, 1988), pp Petzer A. L., Bilgeri R., Geisen F.H., Zilian U., Haun M., Braunsteiner H. and Konwalinka G. (1992) Inhibitory activity of 2- chlorodeoxyadenosine and antagonization by deoxyctidine: Investigations on human normal and chronic myelogenous leukemia hematopoietic progenitor cells (CFU-GM, BFU-E, CFU-E). Molecular Biology of Haematopoiesis 1992 Vol 2, Intercept Ltd., ed. by N. G. Abraham et. al., 60, , Buchartikel 4. Konwalinka G., Helson C., Bravermann S., Petzer A, Bilgeri R., Zilian U., Geisen F., Mittelman A., Abraham N., Ahmed T., Helson L. (1992) Growth inhibitory properties of 2-chlorodeoxyadenosine (2-CdA) against human nervous system tumors. Molecular Biology of Haematopoiesis 1992 Vol 2, Intercept Ltd., ed. by N. G. Abraham et. al., 55, , Buchartikel 15

16 IV. Abstracts Vor der Habilitation: 1. Schulz T.F., Petzer A., Stauder R., Eigentler A. and Dierich M.P. (1986) Expression of CR2(C3d/EBV-receptor) on HTLV-1- transformed human T-cells. Immunobiol., 173, Schulz T.F., Pernegger G., Petzer A., Eigentler A., Myones B.L., and Dierich M.P. (1987) Growth control of B-lymphoblastoid cells by CR2: Stimulation or Inhibition is dependent, upon the individual or simultanous engagement of suitable CR2 epitopes. Complement 4, Pernegger G., Schulz T.F., Myones B.L., Eigentler A., Petzer A. and Dierich M.P. (1987) Stimulation of the C3d/EBV-receptor, CR2, results in the enhanced growth of a Burkitt-lymphoma cell line. Immunobiology, Vol. 175, 4, 366; L Petzer A., Schulz T. F., Möst J., Hosp M., Topar G., Konwalinka G. and Dierich M. P. (1988) Analysis of CR2 Expression on Raji cells stimulated by anti-cr2 monoclonal antibodies in serum free medium. Blut,Vol. 57, 4, 187; Konwalinka G., Wiedermann C. W., Petzer A., Grünewald K., Breier Ch., Patsch J., Geissler D. and Braunsteiner H. (1988) Release of burst promoting activity from accessory cells by insulin: measurement in a serum-free system. Blut, Vol. 57, 4, 185, Geissler D., Greil R., Stauder R. Petzer A., Schulz T., Dierich M. P., Huber H. and Konwalinka G. (1988) Involvement of an 85 kd T- cell activation antigen in the modulation of committed hematopoetic progenitor cells in vitro. Blut, Vol. 57, 4, 254,

17 7. Bilgeri R., Geissler D., Freshney M., Petzer A., Wiedermann C.W., Zwierzina H., Pragnell I., Konalinka G. and Braunsteiner H. (1988) Evaluation of T-lymphocytic and pluripotent stem cell cloning efficiency in patients with myelodysplatic syndrome. Blut, Vol. 57, 4, 255, Hosp M., Topar G., Möst J., Schulz T.F., Petzer A.L. and Dierich M.P. (1988) The synthesis and expression of CR2 on Raji cells is enhanced by a factor in human serum. Immunobiol., Vol. 178, Pernegger G., Schulz T.F., Petzer A., Eigentler A., Myones B.L. and Dierich M.P. (1988) Growth control of cultured B- lymphoblastoid cells by C3d/EBV-receptor (CR2) under serum free conditions. Zbl. Bakt. Hyg. A 268, Petzer A.L., Bilgeri R., Zilian U., Haun M., Geisen F., Konwalinka G. (1991) 2-Chlorodeoxyadenosine inhibits colony growth of myeloid progenitor cells (CFU-e, BFU-e, CFU-gm) in vitro. Int.J.Cell Cl., Vol. 9, No 4, Petzer A.L., Bilgeri R., Zilian U., Haun M., Konwalinka G. (1991) The effect of 2-Chlorodeoxyadenosine on granulocytic, erythroid and T-lymphocytic colony growth. Schweiz.med. Wschr., 121, Suppl Petzer A.L., Bilgeri R., Zilian U., Geisen F., Konwalinka G.(1991) 2-Chlorodeoxyadenosine (CdA): Its inhibitory effect on granulocytic erythroid and T-lymphocytic colony growth.onkologie, 14, suppl. 2,

18 13. Bilgeri R., Petzer A.L., Zilian U., Haun M., Geisen F., Konwalinka G. (1991) CdA-mediated growth inhibition of normal human myeloid progenitor cells can partially be anatagonized by deoxycytidine. Onkologie, 14, suppl. 2, Bilgeri R., Petzer A.L., Zilian U., Haun M., Geisen F., Konwalinka G. (1991) Effect of deoxycytidine on CdA-mediated growth inhibition of normal human myeloid progenitor cells. Int.J.Cell Cl., Vol. 9, No 4, Bilgeri R., Petzer A.L., Zilian U., Geisen F., Haun M., Konwalinka G. (1992) Protective effect of deoxycytidine on 2-CdA treated human bone marrow cultures. Ann. Hematol., Vol. 65, suppl., Petzer A.L., Bilgeri R., Zilian U., Geisen F., Haun M., Herold M, Konwalinka G. (1992) 2-Chloro-2 -deoxyadenosine (CdA) affects myeloid progenitors but not stromal cells in normal human long-term bone marrow cultures (LTBMCs). Ann. Hematol., Vol. 65, suppl., Bilgeri R., Petzer A.L., Zilian U., Geisen F., Haun M., Konwalinka G. (1992) Protective effect of deoxycytidine on 2-CdA treated human bone marrow cultures. Ann. Hematol., Vol. 65, suppl., Petzer A.L., Bilgeri R., Zilian U., Geisen F., Haun M., Herold M, Konwalinka G. (1992) Dose dependent growth-inhibitory effect of 2- Chloro-2 -deoxyadenosine (CdA) in normal human long-term bone marrow cultures (LTBMCs). Ann. Hematol., Vol. 65, suppl.,

19 19. Konwalinka G., Petzer A., Geisen F.H., Schirmer M., Zilian U., Haun M., Braunsteiner H. (1993) A differential sensitivity to 2- chlorodeoxyadenosine (2-CdA) between normal and chronic myeloid leukemic bone marrow erythroid and myeloid progenitor cells. Exp. Hematol.Vol. 21, 1072 (227). 20. Petzer A.L., Geisen F.H., Bilgeri R., Zilian U., Haun M., Herold M, Braunsteiner H., Konwalinka G. (1993) Growth inhibitory effect of 2-chloro-2'-deoxyadenosine (CdA) on myeloid progenitors in normal human long- term bone marrow cultures; compensation by interleukin-3 and granulocyte colony stimulating factor.exp. Hematol.Vol. 21, 1054 (162). 21. Petzer A.L., Geisen F., Bilgeri R., Zilian U.,, Haun M., Herold M, Braunsteiner H., Konwalinka G. (1993) The growth-inhibitory effect of 2-Chloro-2 -deoxyadenosine (CdA) on myeloid progenitors (CFU- GM) in normal human long-term bone marrow cultures can be compensated by the addition of Interleukin-3 (IL-3) or granulocyte colony-stimulating factor (G-CSF). Ann. Hematol., Vol. 67, suppl., Schirmer M, Hilbe W, Geisen F, Fend F, Knoblechner A, Thaler J, Zilian U., Petzer A.L, Konwalinka G. (1994) Monoclonal antibody B-Ly7: Detection of minimal residual disease after treatment of hairy cell leukemia with 2-Chlorodeoxyadenosine. Exp. Hematol.Vol.22, 798 (454). 23. Petzer A, Ponchio L, Ghaffari S, Cashman J, Lansdorp P, Eaves A, Eaves C. (1994) Mobilization of normal LTC-IC in the blood of untreated CML patients with high WBC counts. Blood Vol. 84, No.10, Suppl 1, 400a. 19

20 24. Petzer AL, Lansdorp PM, Hogge DE, Reid D, Eaves CJ. (1995) CD34 ++/ CD38 - cells isolated from normal human marrow can selfrenew and can be extensively amplified in vitro in defined media. J.Hematother. Vol. 4, No. 3, 236 (146). 25. Petzer AL, Lansdorp PM, Shaw G, Barnett MJ, Eaves AC, Eaves CJ. (1995) Elevated numbers od CD38 -, Thy-1 + LTC-IC are present in the blood of newly diagnosed CML patients and include both Ph - and Ph + genotypes. Exp. Hematol.Vol. 23, No. 8, 791 (176). 26. Petzer AL, Lansdorp PM, Hogge DE, Reid D, Eaves CJ. (1995) Extensive amplification of LTC-IC in single cell cultures of normal adult human CD34 ++ /CD38 - marrow cells maintained in defined media. Exp. Hematol. Vol. 23, No. 8, 845 (358). 27. Bockhold K, Petzer A, Eaves C, Hogge D. (1995) Growth factor requirements and phenotypic characterization of human megakaryozyte (Mk) progenitors. Blood Vol. 86, No. 10, suppl 1, 346a (1445). 28. Zandstra PW, Petzer AL, Eaves CJ, Piret JM. (1995) Very high concentrations of cytokines are required for the maximal stimulation in vitro of primitive human hematopoietic progenitors (LTC-IC) and are depleted most rapidly by subpopulations of cells that are highly enriched in their LTC-IC content. Blood Vol. 86, No. 10, suppl 1, 422a (1676). 29. Maguer-Satta V, Petzer A, Ponchio L, Eaves A, Eaves C. (1995) Evidenc eof BCR-ABL gene expression in single CML cells at phenotypically defined and functionally characterized early as well as later stages of hematopoietic cell differentiation. Blood Vol. 86, No. 10, suppl 1, 527a (2095). 20

21 30. Petzer AL, Zandstra PW, Piret JM, Eaves CJ. (1995) The effects of Flk2/Flt3 ligand (FL), Steel factor (SF) and Interleukin 3 (IL-3) are additive and together stimulate an extensive and rapid expansion of primitive cells (LTC-IC) in low density serum-free cultures of CD34 + CD38 - human marrow cells. Blood Vol. 86, No. 10, suppl 1, 493a (1960). 31. Petzer AL, Eaves AC, Eaves CJ. (1995) Rapid loss of the defining attributes of CML LTC-IC in cultures of Ph + CD34 + CD38 - cells maintained in serum-free cytokine-supplemented medium under conditions that stimulate extensive amplification of normal LTC-IC. Blood Vol. 86, No. 10, suppl 1, 601a (2391). 32. Maguer-Satta V, Petzer A, Ponchio L, Eaves A, EavesC (1996) Primitive as well as mature subpopulations of neoplastichematopoietic cells from patients with chronic myeloid leukemia express BCR-ABLmRNA. Brit. J. Haematol, Vol. 93, Suppl 2, 1996, p a. 33. Cashman J, Conneally E, Petzer A, Eaves C. (1996) Characterization of lympho-myeloid stem cells in human cord blood using a quantitative in vivo mouse reconstitution assay. Exp. Hematol.Vol. 24, No. 9, 1035, 66ª. 34. Petzer AL, Eaves AC, Eaves CJ. (1996) Decline of CML (Ph + ) CD34 ++ CD38 - LTC-IC under culture conditions that stimualte expansion of coexisting normal (Ph - ) LTC-IC. Exp.Hematol.Vol. 24, No. 9, 1133, 592a. 21

22 35. Conneally E, Cashman J, Petzer AL, Eaves CJ. (1996) In vitro expansion of human lympho-myeloid stem cells from cord blood demonstrated using a quantitative in vivorepopulating assay. Blood Vol.88, No. 10, Suppl. 1, 628a, (2501). 36. Petzer AL, Zandstra P, Lansdorp PM, Piret J, Eaves CJ. (1996) Significant Expansion of primitive CD34 ++ CD38 - hematopoietic cells (LTC-IC) from human bone marrow in serum-free medium. Acta Med Aust Vol. 23, Sonderheft 1, 1996, Petzer AL, Eaves AC, Eaves CJ. (1996) Establishment of serum-free culture conditions in which CML (Ph + ) CD34 ++ CD38 - LTC-IC decline but coexisting normal (Ph - ) LTC-IC expand. Ann Hematol, Vol. 73, Suppl II, A 96, 382a. Nach der Habilitation: 38. Petzer AL, Eaves AC, Gastl G, Eaves CJ. (1997) Selective Expansion of normal (Ph - ) stem cells (LTC-IC) in cytokinesupplemented cultures from patients with CML. Onkologie, Vol. 20, Sonderheft, p17, 54a. 39. Petzer AL, Eaves AC, Gastl G, Eaves CJ. (1998) In-vitro expansion of normal (Ph - ) stem cells (LTC-IC) in cytokine supplemented cultures from patients with chronic myeloid leukemia. Acta Med. Austriaca, Suppl. 46, 46, p Petzer AL, Gunsilius E, Zech N, Nussbaumer W, Hoflehner E, Gastl G. (1998) Viability cell counts do not predict survival of mature (CFC) and immature progenitor cells (LTC-IC) from apheresis products after overnight storage. Bol. Soc. Bras. Hematol. Hemot. 20 (Suppl). P 30, A

23 41. Petzer AL, Eaves AC, Barnett M, Gastl G, Eaves CJ. (1998) Selective expansion of normal (Ph - ) stem cells (LTC-IC) in chronic myeloid leukemia. Annals of Hematology, Suppl. II to Vol. 77, S 25, Petzer AL, Gunsilius E, Zech N, Clausen J, Hoflehner E, Gastl G. (1999) Evaluation of optimal survival of mature (CFC) and immature progenitor cells (LTC-IC) from apheresis products after overnight (ON) storage. Bone Marrow Transplantation, Vol. 23, Suppl. 1, S 206, Clausen J, Vergeiner B, Petzer AL, Gastl G, Gunsilius E. (1999) Impaired ex-vivo expandability of CD56+ cytotoxic lymphocytes in autologous PBSC transplants from breast cancer patients. Bone MarrowTransplantation, Vol. 23, Suppl. 1, S 25, Gunsilius E, Petzer AL, Stockhammer G, Nussbaumer W, Clausen J, Schumacher P, Gastl G. (1999) Platelets contribute the most to vascular endothelial growth factor levels in peripheral blood. Haematologica, PO Petzer AL, Gunsilius E, Zech N, Clausen J, Hoflehner E, Gastl G. (1999) Evaluation of optimal survival of immature progenitor cells (LTC-IC) from apheresis products under different overnight (ON) storage conditions. Cytotherapie, Vol. 1, No. 3, p217, O Zech N, Gunsilius E, Clausen J, Hoflehner E, Gastl G, Petzer AL (1999) Expansion of apheresed PBPC under clinically applicable conditions. Onkologie 21, suppl. 1,